October 8, 2019 — ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).
"We will now be able to adapt the therapy to changes in the patient's body such as movement caused by breathing or digestion, to target cancer more accurately and deliver radiation only when the tumor is in the proper position," said Daphne Haas-Kogan, M.D., chair Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center.
The new MRI-guided radiation therapy will be used to treat many different cancer types. Its greatest potential advantage will be in treating soft-tissue tumors – including breast, gastrointestinal, gynecological, prostate, pancreas, sarcoma, and head and neck tumors – and for tumors that are highly mobile, such as lung cancers.
"This new technology offers substantial clinical benefit by providing greater resolution of soft tissue tumors, allowing for more precise tumor targeting and less radiation exposure thus sparing healthy tissue," said Raymond Mak, M.D., lead radiation oncologist for MRI-guided radiation therapy at Dana-Farber/Brigham and Women's Cancer Center. "This cutting-edge technology allows us to personalize and adapt each treatment in ways we never could before."
For more information: www.viewray.com
September 29, 2026 
